These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27045720)

  • 1. [Expression of FAS-AS1 in breast cancer and its effect on the host gene sFas].
    Zhou SW; Su BB; Zhou Y
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):949-53. PubMed ID: 27045720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.
    Sehgal L; Mathur R; Braun FK; Wise JF; Berkova Z; Neelapu S; Kwak LW; Samaniego F
    Leukemia; 2014 Dec; 28(12):2376-87. PubMed ID: 24811343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway.
    Yang Y; Yang H; Xu M; Zhang H; Sun M; Mu P; Dong T; Du S; Liu K
    Hum Cell; 2018 Jul; 31(3):232-241. PubMed ID: 29679339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
    El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
    Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction.
    Lee SH; Kim SY; Lee JY; Shin MS; Dong SM; Na EY; Park WS; Kim KM; Kim CS; Kim SH; Yoo NJ
    Lab Invest; 1998 Apr; 78(4):453-9. PubMed ID: 9564889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
    Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
    Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Fas in serum from patients with renal cell carcinoma.
    Nonomura N; Nishimura K; Ono Y; Fukui T; Harada Y; Takaha N; Takahara S; Okuyama A
    Urology; 2000 Jan; 55(1):151-5. PubMed ID: 10654915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Fas in malignant pleural effusion and its expression in lung cancer cells.
    Mitani K; Nishioka Y; Yamabe K; Ogawa H; Miki T; Yanagawa H; Sone S
    Cancer Sci; 2003 Mar; 94(3):302-7. PubMed ID: 12824926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.
    Lee CT; Zhou Y; Roy-Choudhury K; Siamakpour-Reihani S; Young K; Hoang P; Kirkpatrick JP; Chi JT; Dewhirst MW; Horton JK
    Radiat Res; 2017 Aug; 188(2):169-180. PubMed ID: 28598289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
    Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
    Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome.
    Islam Z; Jahan I; Ahammad RU; Shahnaij M; Nahar S; Mohammad QD
    PLoS One; 2018; 13(2):e0192703. PubMed ID: 29432441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Fas mRNA is dominantly expressed in cases with silicosis.
    Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Kawakami Y; Kusaka M; Ueki H; Kita S; Ueki A
    Immunology; 1998 Jun; 94(2):258-62. PubMed ID: 9741350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating soluble Fas in patients with breast cancer.
    Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
    World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
    Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
    Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
    Li W; Li N; Kang X; Shi K
    Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.
    Kamihira S; Yamada Y
    Leuk Lymphoma; 2001 Mar; 41(1-2):169-76. PubMed ID: 11342370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo.
    Perabo FG; Mattes RH; Wirger A; Steiner G; Kamp S; Schmidt D; Pegelow K; von Ruecker A; Müller SC
    Urol Oncol; 2001 Jul; 6(4):163-169. PubMed ID: 11418323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3.
    Hewala TI; Abd El-Monaim NA; Anwar M; Ebied SA
    Pathol Oncol Res; 2012 Oct; 18(4):841-8. PubMed ID: 22422199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Fas antigen in uremia accelerates adhesion of mononuclear cells to endothelial and sinovial cells via stimulated hyaluronan production.
    Matsumoto J; Yanagisawa N; Konoma T; Haizuka H; Nakashima Y; Sato M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S54-7. PubMed ID: 11576923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.